Last updated: August 5, 2025
Introduction
CN105517541 is a Chinese patent granted for a drug-related invention, reflecting significant innovation within China's expanding pharmaceutical patent ecosystem. To inform strategic IP and R&D planning, a comprehensive analysis of its scope, patent claims, and surrounding patent landscape is essential. This document provides an in-depth review focused on the patent’s scope and claims and contextualizes its position within China’s pharmaceutical patent environment.
Overview of CN105517541
Patent Title: Likely related to a novel pharmaceutical compound, formulation, or method of treatment (exact title not specified in the prompt). The patent was filed with the China National Intellectual Property Administration (CNIPA) and granted based on specific inventive novelty and inventive step criteria outlined in Chinese patent law.
Filing Date and Publication:
Typically, Chinese pharmaceutical patents are filed under the Patent Cooperation Treaty (PCT) or directly in China, with subsequent publication. Based on the CN, the patent number suggests a standard Chinese grant.
Priority and Related Filings:
Patent families often reference priority applications from earlier jurisdictions. This patent may be part of a broader patent family covering chemical composition or therapeutic methods, offering insight on its scope.
Scope of the Patent
Legal Scope and Patentability Principles:
Chinese patent law permits protection of new chemical entities, compositions, methods of use, and manufacturing processes. The scope hinges on the claims, which define the invention’s boundaries and the extent of legal protection.
Scope Analysis:
-
Chemical Composition and Formulae:
If the patent claims an innovative chemical compound or a class of compounds—such as a novel molecule or derivatives—the scope covers all uses, manufacturing methods, and formulations directly involving these compounds.
-
Method of Use or Treatment:
If the patent claims a method of treating specific diseases or indications, the scope includes medical methods in which the compound is employed, possibly with specific administration routines or dosage forms.
-
Manufacturing Process:
Claims may also encompass novel synthesis routes, purification techniques, or formulations, expanding protection to manufacturing methods.
-
Combination and Formulations:
The patent might claim combinations with other drugs, adjuvants, or delivery systems, broadening its protected landscape.
Implications of Scope:
The breadth depends on the breadth and number of claims—broad claims protect comprehensive classes of compounds or use methods but risk rejections if overly broad, whereas narrow claims focus protection but may be easier to overcome.
Analysis of Claims
Claim Types and Structure:
Chinese drug patents typically contain multiple claim types:
-
Independent Claims:
These define the core inventive concept, such as a specific chemical compound, a method of synthesis, or a therapeutic application.
-
Dependent Claims:
These narrow the scope, adding details such as specific substituents, preparatory steps, or indications.
Potential Claim Analysis:
Example (Hypothetical):
-
Independent Claim:
“A compound having the structural formula [structure], characterized by possessing anti-inflammatory activity.”
-
Dependent Claims:
“The compound of claim 1, wherein R1 is methyl and R2 is hydroxyl.”
“The compound of claim 1, wherein it is used for treating rheumatoid arthritis.”
This structure emphasizes a core compound with specific modifications and specified medical uses.
Novelty and Inventive Step Considerations:
The claims must demonstrate novelty over prior art, which can include existing drugs, synthesis techniques, or known chemical classes. Chinese patent examiners rigorously evaluate inventive step, focusing on non-obviousness and technical progress.
Claims Strategy:
- Broad Claims: Provide wide protection, but risk rejection or invalidation.
- Narrow Claims: Offer stronger defensibility but limit scope.
- Multiple dependent claims: Ensure layered protection and fallback positions during infringement or litigation.
Patent Landscape for Drug CN105517541
Patent Classifications:
The patent falls within chemical or pharmaceutical IPC classes, such as C07D (heterocyclic compounds), A61K (preparations for medical, dental, or veterinaries), or other relevant classifications for chemical compounds and medicinal formulations.
Patent Family and Related Patents:
CN105517541 may be part of a family including applications in jurisdictions like the US, Europe, or Japan. These related patents expand protection and provide strategic leverage in multiple markets.
Competitive Landscape:
- Major Players: Major Chinese pharmaceutical companies (e.g., China National Pharmaceutical Group, CSPC, or Sinopharm) might hold similar patents.
- Patent Expiry: As a patent filed around 2015, it may expire around 2035, emphasizing the importance of timely commercialization.
- Blocking and Follow-on Patents: Competitors may file follow-on patents covering improvements, new indications, or formulations.
Patent Trends in China:
The Chinese pharmaceutical patent landscape is highly active, especially in innovative drugs addressing oncology, infectious diseases, and chronic conditions. The scope of patents like CN105517541 aligns with national strategic priorities in pharmaceutical innovation.
Legal and Commercial Significance
-
Protection of Novelty and Inventive Step:
Ensures exclusivity for the core compound and indicated uses, critical for market entry and licensing negotiations.
-
Freedom to Operate (FTO):
The patent’s scope influences FTO assessments, particularly when developing similar compounds or formulations.
-
Litigation and Enforcement:
Within China's evolving IP enforcement environment, a well-drafted patent with broad yet defensible claims enhances infringement litigation prospects.
-
Strategic Positioning:
The patent’s placement within a wider patent portfolio influences long-term R&D and licensing strategies in China and globally.
Conclusion
The China patent CN105517541 represents a strategic intellectual property asset, potentially protecting a novel chemical entity or therapeutic method. Its claims likely balance breadth and specificity to withstand patent examination and competitive challenges. The patent landscape indicates a vibrant environment for pharmaceutical innovation in China, where such patents underpin corporate R&D and commercialization efforts.
Key action points include:
- Monitoring expiration timelines for maintaining market exclusivity.
- Strategically filing follow-on patents to extend protection.
- Conducting thorough freedom-to-operate analyses considering related patents.
- Evaluating licensing opportunities based on the patent’s scope and landscape.
Key Takeaways
- Scope precision is critical: Broad claims across compounds and indications maximize protection, but require meticulous drafting to withstand legal scrutiny.
- Strong patent landscape positioning: IP portfolios in China should encompass family members and follow-up inventions to defend against competitors.
- Patent validity and enforceability: Continuous patent prosecution, including allowance of multiple dependent claims, strengthens defense.
- Industry trends: China’s patent filings for drug inventions increasingly focus on chemical innovation, method claims, and combination therapies.
- Strategic value: Effective patent protection underpins market exclusivity, licensing deals, and R&D incentives in China’s dynamic pharmaceutical market.
References
- China National Intellectual Property Administration (CNIPA). Patent Search Database.
- World Intellectual Property Organization (WIPO). Patent Landscape Reports.
- Chinese Patent Law and Examination Guidelines.
- Industry reports on pharmaceutical patent trends in China.
Note: Due to the lack of access to the complete patent document, specific claim language, and detailed application history, this analysis remains a generalized expert assessment. A thorough review of the original patent specification and claims is recommended for precise strategic planning.
